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Summary: Clinical features and mortality due to human immunodeficiency 
virus type-1 (HIV-1) infection in women are described as part of a prospective 
4-year cohort study on perinatal transmission of HIV in Kigali, Rwanda. Two 
hundred f i feen HIV-seropositive (HIV +) and 216 HIV-seronegative (HIV -1 
pregnant women were enrolled at delivery between November 1988 and June 
1989. Clinical information collected during systematic quarterly examinations 
was compared. HIV antibody tests were performed at delivery and CLWCDS 
lymphocyte counts at 15 days' postpartum. HIV - women who seruconverted 
during the follow-up period were excluded from the analysis of the comparison 
group starting at the date of seroconversion. At enrollment, all HIV + women 
were asymptomatic for acquired immune deficiency syndrome (AIDS). Inci- 
dence of tuberculosis was 2.9 per 100 women-years (WY) after 4 years of 
follow-up in HIV+ women versus 0.2 per 100 WY among HIV- women 
(relative risk, 18.2; 95% confidence interval 2.4-137.0). Among HIV + women, 
the incidence of AIDS (World Health Organization clinical AIDS definition) 
was 3.5 per 100 WY. The mortality rate was 4.4 per 100 WY among HIV+ 
women versus 0.5 per 100 WY among HIV- women. Clinical AIDS was 
Dresent in onlv half of the fatalities. Tuberculosis was a major cause of mor- . . .  . . : . 
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In Africa, although the male-to-female sex ratio is 
close to 1:l for AIDS cases, estimates of the HIV 
seroprevalence among young adults frequently give 
higher figures for women than men. In population- 
based HIV serosurveys performed in Uganda in 
1989, women had an infection rate 1.4 times higher 
than that for men (4). Similar observations have 
been made in Rwanda (5). 
The clinical aspects and the natural history of 
HIV infection among women have been primarily 
documented in Europe and in the United States (6- 
9). In these women, injecting drug use is the major 
risk factor for acquisition of HIV infection. It is 
conceivable that such observations cannot be ex- 
trapolated to African women who acquire HIV in- 
fection most likely by heterosexual intercourse, live 
in a very different socioeconomical and microbio- 
logical environment. and whose clinical manage- 
ment is also much more limited. At the present, few 
data are available on the specific characteristics of 
the natural history of HIV infection in African 
women (10). 
The aim of this study is to describe events occur- 
ring over a 4-year prospective clinical follow-up in 
an already existing cohort of HIV-infected women 
after delivery in Kigali, Rwanda, in order to ulti- 
mately provide recommendations for improving the 
quality of care in this African environment. 
SUBJECTS AND METHODS 
In an ongoing prospecure cohort study on mother-to-child 
transmission of HIV-1, two groups of HIV-seropositive (HIV +) 
and seronegative (HIV- I women were enrolled at delivery at 
the maternity ward of the Centre Hospitalier de Kigali (CHK) 
and followed up. Details of the enrollment and follow-up proce- 
dures have been published elsewhere (1 1.12). Briefly, HIV 
testing was systematically offered between November 1988 
and June 1989 to all women delivering in the matemity ward of 
the CHK and accepting the principles of the study. We enrolled 
consecutively those women who fulfilled the following inclusion 
criteria: delivering a live living permanently within the 
city limits, and giving informed consent to participate. A group 
of HIV- women of comparable maternal age and parity was 
consecutively selected as a comparison group. Pretest infoma- 
tion, objectives. constraints. and benefits of the study were re- 
lated to each \voman at dciivery by a trained social worker. 
Posttest counselling was given to those who wanted to know 
their HIV serostatus or those of their children during the study 
period. 
The women were systemaridly examined at 3-month inter- 
vals over the 4 years of follow-up by practitioners who were 
blinded to the HIV SerostZNs and focused on signs and symp- 
toms of the World Health Ckganization (WHO) clinical case def- 
inition for AIDS in adults (13). A standardized questionnaire was 
applied during each cons~nt ion  to collect data on symptoms 
and hospitalizations occumng during the past trimester. Medical 
care was provided free of charge in both groups throughout the 
study period. 
At delivery, a blood sample was collected from the mother and 
tested for HIV antibodies by a commercial enzyme linked im- 
munosorbent assay (ELISA), Vironostika, Organon Teknika) 
and confirmed by a commercial Western blot (WB) technique 
(Du Pont de Nemours) with use of the Centers for Disease Con- 
trol criteria of interpretation (14). All HIV- women were 
retested for HIV antibodies every 3 months during follow-up 
to detect possible seroconversions. Recent syphilis was diag- 
nosed at delivery by dual positive nontreponemal test (VDRL, 
latex Wellcome) and treponemal test (TPHA. Wellcome). 
CD4 and CD8 lymphocyte counts were carried out by an 
indirect immunofluorescence technique at  2 weeks’ post- 
partum. A CD4/CD8 ratio of <OS defined severe immunodefi- 
ciency (15). 
Tuberculosis was confirmed if sputum smears stained by the 
Ziehl-Nielsen technique revealed typical alcohol acid-resistant 
bacilli or if Mycobacterium tuberculosis was obtained by culture 
of smears on Lowenstein medium, or isolated from pleural or 
lymph node biopsies, It was considered probable otherwise on 
the observation of a clinical improvement under tuberculosis 
treatment (three-drug regimen during 6 months). 
HIV -I- women were compared to HIV - women for morbidity 
and mortality. When a seroconversion occurred in an HIV- 
woman, she was excluded from the comparison group from 
the &te of diagnosis of her seroconversion. Clinical outcomes 
were studied with use of available information collected by stan- 
dardized follow-up questionnaires and hospital records (16). In- 
cidence density rates of symptoms (expressed as rates per 
100 women-years [WU]), clinical signs, and diseases such as 
tuberculosis were computed. A research of women lost to fol- 
low-up at four years was performed by a radio call in the city. 
Women who were known alive at that time but could not be 
examined contributed to the denominator for the survival anal- 
ysis. 
Chi-square test, Fisher’s exact test, and Student’s I test were 
used for comparisons, with a significance level of 0.05. Relative 
risks IRR) were computed to measure the strength of association 
for incidence density rates with their 95% confidence intervals 
(CI) according to the semi-exact merhod. 
For HIV+ women, cumulative probabilities of survival and of 
remaining AIDS-free were computed according to the Kaplak- 
Meier product limit method and their 95% CI by Rothman’s for- 
mula (17). Univariate analysis and the descendant stepwise IO- 
gistic regression model were used to study the determinants of 
mortality in relation to maternal characteristics recorded at the 
time of delivery. The following variables were studied as poten- 
tial risk factors: age <25 years, reproductive history with at least 
one spontaneous abortion, unstable sexual relationship, IOW in- 
come. presence of clinical signs and symptoms of HIV infection. 
and CD4/CD8 ratio <O.S. 
RESULTS 
Details about the results obtained at enrollment in 
the study have been given elsewhere (11,12). In 
brief. the two groups of 215 HIV+ and 216 HIV - 
women gave 218 live births, respectively. The mean 
maternal age was 25.1 years (SD: 4.5 years) and the 
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otd number of pregnancies was 2.7 (SD: 1.8). The 
ropofiion of women living in a stable relationship, 
marriage, or common-law union. tended to be 
lower in the HIV+ group (83%) than in the HIV- 
" goup ( ~ 9 % ~  p = 0.06). HIV + mothers did not dif- 
,. . .fer from HIV- mothers in terms of occupation, 
monthly income, and place of origin. The HIV- 
' *others enrolled and those screened but not en- 
F&ed were similar in terms of socioeconomic sta- 
tgs. Between delivery and day 15 postpartum, the 
drop-out rate in the HIV- group enrolled (16% ofn  
= 257) was not statistically different from that 
,among the HIV+ group (21% of n = 273). Predom- 
inant reasons for drop out were refusal of the hus- 
bands and false address given by the mothers. 
Two weeks after delivery, no HIV i woman ful- 
WHO definition for clinical AIDS. The 
rences between HIV + and HIV - women 
.were for chronic cough and history of .herpes 
zoster, more frequently reported by HIV + women 
thah by HIV- women (6 vs. 3%, p = 0.08; and 2 
vs. O%, p = 0.05, respectively). In contrast to the 
city of clinical signs and' symptoms, 72.4% of 
HIV+ women (n = 18.5) had a CD4/CD8 ratio 
10.1% of the HIV- women in = 197) (p 
Profound immunosuppression was ob- 
24.3% of the HIV + women and in 3.0% of 
women. There was no si-&'îcant differ- 
een the two groups for the presence of. 
antibodies, with an overall, prevalence of 
Oh88 = 16% in the HIV+ goup,  and 19/ 
Óverall, the mean length of clinical follow-up was 
..9 months (SD = 16 months). HIV- women ac- 
., . .
.. 
in the HIV- group). . ' 
ted for 594 WY of clinical follow-up. and 
women for 637 WY (Table 1). Clinical fol- 
taking into account the additional information pro- 
vided by those women who died (n = 29>, serocon- 
verted (n = 20), or were lost to clinical follow-up 
before the end of the fourth year (n = 176), 76% of 
the theoretical clinical follow-up of the cohort was 
available for the evaluation of the morbidity (Table 
1). There were no si-gnifkant differences in terms of 
demographic or clinical characteristics at time of 
inclusion of the women who were clinically fol- 
lowed up over the study period compared with 
those lost to follow-up (data not shown). After the 
radio call in the city, 299 women were known to be 
alive after 4 years, accounting for 690 WY of sur- 
vival in HIV+ women and 727 WY in HIV- 
women (Table 1). These figures were used for the 
evaluation of mortality. 
Over the entire follow-up period, there were sta- 
tistically significant differences between HIV + and 
HIV- women for the occurrence of each of the 
clinical signs and symptoms of the clinical A I D S  
case definition (Table 2). Weight loss, defined as the 
loss of 10% or more of the body weight measured at 
3-month postpartum, generalized lymphadenopa- 
thy, generalized pruritis dermatitis, and persistent 
cough were the most frequently reported symptoms 
in the group of HIV+ women after 4 years of fol- 
low-up. However, herpes zoster was the sign most 
strongly associated with HIV infection (22 epi- 
sodes) for a RR of 7.9 (Table 2). 
Seventeen cases of tuberculosis (seven pulmo- 
nary, eight extrapulmonary, and two disseminated), 
of which 14 were confirmed bacteriologically, were 
diagnosed in HIV + women versus one case of ex- 
trapulmonary tuberculosis confirmed in an HIV - 
woman. Overall, the incidence of tuberculosis was 
2.86 per 100 WY in HIV+ women and 0.16 per 100 
WY among HIV - women during the 48 months of 
The incidence density rate of hospitalizations was 
~ 
1 . -  follow-up (RR, 18.2; CI, 2.4-137.0). 
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TABLE 2. Incidence densiry rates per 100 women-years ( WY) of signs and symproms among human immunodeficiency virus type 1 
!- 
t‘ 
HIV - HIV - 95% Confidence r 
i 
(HIV-I)-infected (HIV+)  and uninfecled (HIV-) women during rhe f irst 48 months of folfow-up t Kigali, Rwanda, 1998-1993) 
?- 
p Value“ Sign of symptom women women Relative risk interval 
L 
2.1 1.4-3.1 o.ooo1 f Weight loss 2 10% baselineb 12.6 5.9 
chronic diarrhea (31 month)b 5.1 1.7 3.2 1 L 4 . 2  0.0012 , 
Generalized lymphadenopathy‘ 28.8 16.3 1.8 1 A2.2 o.ooo1 
Persistent cough (31 month)’ 9.1 4.1 2.2 1.4-3.6 O.oo08 
Generalized pruntis dermatitis‘ 10.1 4.1 2.4 1.6-3.9 o.ooo1 
Herpes zostef 3.7 0.4 7.9 2.4-26.3 O .o002 
Oropharyngeal candidiasis‘ 5.2 1.3 4.2 13-9.0 O.CC02 
AIDS (WHO case definition)’ 3.5 
prolonged fiver (2 1 month)b 6.1 2.2 2.8 1.5-5.1 0.0015 
¿ 
i 
- - - - 
L; 
t 
I AIDS. acquired immune deficiency syndrome: WHO. World Health Organization. u Chi-square test. 
Major sign of the WHO AIDS case definition. 
‘ Minor sign of the WHO AIDS case definition. 
See definition in text. 
., sis (3); malaria (2), encephalitis (1). and, surgical 
complications (I). Only 12 of these 26 deaths (46%) 
were in women presenting with clinical AIDS at the 
. time of death, but 22 were possibly‘HIV related. In 
HIV- women, one died of surgical complications 
during the early postpartum period. one of epileptic 
fit, and the last one of an encephalitis of unknown 
: Among the 16 maternal variables studied b i  uni- 
. . etiology. 
13.9 per 100 among HIV+ women versus 9.5 
per 100 WY in the HIV- group (p=O.Ol) (Table 3). 
Twenty-one women developed clinical AIDS dur- 
ing follow-up, all in the HIVI- group (3.5 per 100 
WU). The cumulative probability of remaining 
ADS-free among HIV+ women was 97.4% after 
12 months of follow-up (CI, 94-99%), 95.5% after 24 
months (CI, 91-98%), and 85.9% after 48 months 
(CI, 79-91%) (Fig. 1). 
Although the occurrence of AIDS was rare in 
these HIV+ women, 26 of them (12.1%) died over 
the 4-year period versus three among HIV- 
women (1.4%). Women known to be alive after 4 
years accounted for 87.7% of the theoretical follow- 
up for survival analysis (Table 1). The mortality rate 
was 4.4 per 100 WY among HIV+ women versus 
0.5 per 100 WY among HIV - women (RR, 9.3; CI, 
2.8-30.7). The cumulative probability of survival 
for’HIV+ women was 98.6% at 12 months (CI, 
95.7-99.5%), 93.6% at 24 months (CI. 89.0-%.3%), 
and 85.5% at 48 months (CI, 79.1-90.2%) (Fig. 2). 
The causes of death among HIV+ women were 
identified in 24 out of the 26 cases (92%): tubercu- 
losis (81, persistent diarrhea (6), pneumonia (3), sep- 
Í 4). Nine of these variables were introduced in the ! 
multivariate logistic regression model. The only pa- 
rameter significantly associated with 4-year mortal- 
ity in HIV + women was the presence of persistent 
cough (p = 0.048; odds ratio, 2.66; CI, 1.01-7.01). 
DISCUSSION 
Although women are estimated to represent more 
than half of the population of HIV-infected people 
worldwide (2), very few data are available on the 
natural history of HIV infection in women. The 
present study is an attempt to partially fdl this gap 
in an African setting, providing long-term follow-up 
information. Our evaluation of the natural history of 
HIV infection had to suffer, however, a major con- 
straint because of its prevalent cohort design (18). 
Indeed, the ideal way to describe the natural history 
of HIV infection is to follow incident cohorts. Such 
groups are difficult to identify and enroll, particu- 
larly in Africa. The main objective of our cohort 
study was the evaluation of the mother-to-child 
transmission rate of HIV. The women participating 
in our study, however, had just completed a preg- 
nancy, were mostly asymptomatic at enrollment, 
but had an unknown duration of HIV infection. Our 
clinical observations collected prospectively in a 
systematic fashion with a comparison group of 
HIV- women may be used to approximate the 
“true” natural history of HIV infection in this pop- 
ulation. The follow-up rafe was high enough and 
comparable between the two groups to guarantee 
that unbiased conclusions were drawn from this 
analysis (16). 
In our study, the cumulative probability of reach- 
Vol. 9,  No. 4, 1995 
variate analysis, persistent cough at inclusion was 
the only symptom associated with mortality, (Table 
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TABLE 3. Number and causes of hospitalirarions in rhe IWO 
groups of human immunodeficiency virus type 1 
(HIV-1w.nfecIed ( H I V C )  and uninfected IHIV-)  women 
(Kigali, R.wanda. 1988-1993) 
HIV+ HIV- 
Diagnosis women women 
15 19 blalaria O 
Diarrhea 1 
Pneumonia O 
Tuberculosis O 
Irf eningitis 7, 
Breast abscess O 
Other iniections'' 
Subsequent delivery or gynecological 22 
Postsurgery complications 1 Q 
8 
5 
4 
2 
2 
4 
26 disorders 14 9 
Other causes 
No. of hospital admissions 
J u 
83 61 
0 Ocher infections: oropharyngeal candidiasis ( I ) .  herpes 
~ 
zoster ( 1 1 .  septicemia (2). 
ing the AIDS stage is 4.5% after 2 years of follow-up 
and 13.5% after 4 years in HIV-t- women. These 
figures are consistent with those described by Lin- 
dan and co-workers in another prevalent cohort of 
Rwandan women followed for 2 years (10). In ad- 
dition. when comparing our study with those per- 
formed in other population groups in industrialized 
countries, our figure falls within the range of values 
already obtained, the cumulative probability of de- 
veloping AIDS varying between 17.5% after 4 years 
among European women (7) and 21% among 
women after an index delivery (9). Although these 
studies used various definitions of AIDS and were 
also prevalent studies, this comparison suggests 
that the course of the HIV infection is not dramat- 
ically different in populations of women from indus- 
trialized countries compared with those from Af- 
rica. 
After four years of follow-up, the mortality rate 
among HIV + women was nine times higher than in 
HIV - women. These figures are lower than those 
obtained in a Ugandan rural adult population where 
the annual mortality rate was 11.6% (19,20). This 
difference may be explained by the lack of medical 
care in this rural population in contrast to our co- 
hort or by the prevalent design. More than half of 
the deaths among the HIV-infected group occurred 
in women not fulfilling the clinical definition of 
AIDS in our study. This suggests that the life- 
threatening manifestations of HIV infection in Af- 
rican women are much broader than those strictly 
included in the AIDS case definition, as suggested 
earlier (10,20). Thus, the clinical definition of AIDS 
proposed in Bangui in 1986 may be seen as a tool of 
limited value for the evaluation of HIV-related mor- 
tality (13,21). 
7 
probability of survival (YO) 
. ._ . 
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FIG. 2. Probability of survival among human immunodeficiency virus type 1-infected women (n = 215): Kaplart-Meier product 
limit method (Kigali, Rwanda, 1988-1993). 
In our study, each of the clinical signs and symp- 
toms included in the WHO definition of AIDS was 
observed with increased frequency among HIV + 
women as compared with HIV- women. One of 
the diseases most frequently encountered among 
HIV+ women and also frequently identified as a 
major cause of death was tuberculosis. Indeed, the 
risk of developing tuberculosis was 18 times higher 
for HIV + women than for HIV - women. This fig- 
TABLE 4 .  Univariate analysis-maternal variables at 
inclusion studied as possible determinanrs of 4-year mortality 
(Kigali, Rwanda. 1988-1993) 
Variables ' 5% Decreased Odds 
at inclusion (n = 26) ratio p Value 
Age <25 years 35 1.9 0.11" 
Educational level >5 years 46 0.6 0.31" 
Low income <5 O00 FRW (35 S) 12 1.7 0.27" 
Parity 32 69 0.6 0.62 
One or more abortion 31 1.4 0.23" 
Diarrhea ( 3 1  month) 4 0.7 0.68 
Prolonged fever (3 I month) 4 0.8 0.83 
Weight <50 kg 18 0.9 0.25" 
Herpes zoster 4 0.9 0.92 
Oropharyngeal candidiasis 4 3.7 0.24" 
Generalized pruritis dermatiris 4 1.0 0.97 
Generalized lymphadenopathy O - 0.45 
Persistent cough (31  month) 21 2.6 0.05" 
CD4KDS ratio c0.5 19 0.9 0.82" 
These variables were inrluded in the multivariate andysis 
(logistic regression model). 
Ure is consistent with those found in other cohort 
studies in Africa (22,23). At any stage of HIV infec- 
tion, subjects are at increased risk of reactivating a 
latent M. tuberculosis infection and probably also 
to acquire primary infection (24,25). Thus, the HIV 
epidemic has a striking effect, particularly in Africa, 
on the magnitude of the tuberculosis burden (26,27). 
It is noteworthy that in our multivariate analysis of 
risk factors of death in HIV + women, the only clin- 
ical sign predictive of death is chronic cough at en- 
rollment. This suggests that chronic cough should 
be considered as an early marker of a pejorative 
evolution of HIV infection in relation to tuberculo- 
sis or other pulmonary complications. The fact that 
profound immunosuppression was not predictive of 
mortality does not imply that this epidemiological 
association does not exist. 
plications of HIV infection such as pneumococcal 
infection are readily treatable by appropriate che- 
motherapy, making early clinical management of 
HIV-infected individuals feasible even in the devel- 
oping world (28). In addition, in africa, the evalu- 
ation of pragmatic approaches designed to prevent 
or treat early tuberculosis in HIV-infected patients 
should be considered of utmost priority. In the con- 
text of implementing programs for clinical and psy- 
chosocial management of HIV infecti en of 
com- Tuberculosis as well as c 
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childbearing age should be targeted as they already 
pay a heavy tribute to the HIV pandemic. 
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